Malaria Vaccine Branch, WRAIR, 503 Robert Grant Avenue, Silver Spring, MD 20910, USA.
Malar J. 2013 Apr 22;12:136. doi: 10.1186/1475-2875-12-136.
A lack of defined correlates of immunity for malaria, combined with the inability to induce long-lived sterile immune responses in a human host, demonstrate a need for improved understanding of potentially protective immune mechanisms for enhanced vaccine efficacy. Protective sterile immunity (>90%) against the Plasmodium falciparum circumsporozoite protein (CSP) has been achieved using a transgenically modified Plasmodium berghei sporozoite (Tg-Pb/PfCSP) and a self-assembling protein nanoparticle (SAPN) vaccine presenting CSP epitopes (PfCSP-SAPN). Here, several possible mechanisms involved in the independently protective humoral and cellular responses induced following SAPN immunization are described.
Inbred mice were vaccinated with PfCSP-SAPN in PBS. Serum antibodies were harvested and effects on P. falciparum sporozoites mobility and integrity were examined using phase contrast microscopy. The functionality of SAPN-induced antibodies on inhibition of sporozoite invasion and growth within primary human hepatocytes was also examined. The internal processing of SAPN by bone marrow-derived dendritic cells (BMDDC), using organelle-specific, fluorescent-tagged antibody or gold-encapsulated SAPN, was observed using confocal or electron microscopy, respectively.
The results of this work demonstrate that PfCSP-SAPN induces epitope-specific antibody titers, predominantly of the Th2 isotype IgG1, and that serum antibodies from PfCSP-SAPN-immunized mice appear to target P. falciparum sporozoites via the classical pathway of complement. This results in sporozoite death as indicated by cessation of motility and the circumsporozoite precipitation reaction. Moreover, PfCSP-SAPN-induced antibodies are able to inhibit wild-type P. falciparum sporozoite invasion and growth within cultured primary human hepatocytes. In addition, the observation that PfCSP-SAPN are processed (and presented) to the immune system by dendritic cells in a slow and continuous fashion via transporter associated with antigen processing (TAP) recruitment to the early endosome (EE), and have partially delayed processing through the endoplasmic reticulum, has the potential to induce the long-lived, effector memory CD8+ T-cells as described previously.
This paper describes the examination of humoral and cellular immune mechanisms induced by PfCSP-SAPN vaccination which result in sterile host protection against a transgenic P. berghei malaria sporozoite expressing the P. falciparum CSP, and which significantly inhibits native P. falciparum sporozoites from invading and developing within cultured human hepatocytes. These results may indicate the type and mode of action of protective antibodies needed to control P. falciparum sporozoites from infecting humans as well as a potential mechanism of induction of protective long-lived effector memory CD8+ T-cells.
疟疾的免疫相关性尚未明确,且无法在人体宿主中诱导持久的无菌免疫应答,这表明我们需要更好地了解潜在的保护性免疫机制,以提高疫苗的效果。使用转基因修饰的伯氏疟原虫孢子(Tg-Pb/PfCSP)和自组装蛋白纳米颗粒(SAPN)疫苗来展示 PfCSP 表位(PfCSP-SAPN),已实现针对疟原虫环子孢子蛋白(CSP)的保护性无菌免疫(>90%)。本文描述了 SAPN 免疫接种后诱导的独立保护性体液和细胞应答所涉及的几种可能机制。
用 PfCSP-SAPN 在 PBS 中对近交系小鼠进行疫苗接种。采集血清抗体,并使用相差显微镜检查其对疟原虫孢子运动和完整性的影响。还检查了 SAPN 诱导的抗体对抑制原代人肝细胞内孢子入侵和生长的功能。使用细胞器特异性荧光标记抗体或金包被的 SAPN,分别使用共聚焦或电子显微镜观察骨髓来源的树突状细胞(BMDDC)对 SAPN 的内部加工。
本工作的结果表明,PfCSP-SAPN 诱导了表位特异性抗体滴度,主要是 Th2 同型 IgG1,并且 PfCSP-SAPN 免疫小鼠的血清抗体似乎通过补体的经典途径靶向疟原虫孢子。这导致孢子死亡,表现为运动停止和环子孢子沉淀反应。此外,PfCSP-SAPN 诱导的抗体能够抑制野生型疟原虫孢子在培养的原代人肝细胞中的入侵和生长。此外,观察到 PfCSP-SAPN 通过抗原加工相关转运蛋白(TAP)招募到早期内体(EE)以缓慢而连续的方式被树突状细胞加工(和呈递)到免疫系统,并且通过内质网的部分延迟加工,有可能诱导先前描述的长寿命效应记忆 CD8+T 细胞。
本文描述了 PfCSP-SAPN 疫苗接种诱导的体液和细胞免疫机制的检查,这些机制导致对表达疟原虫 CSP 的转基因伯氏疟原虫疟疾孢子的无菌宿主保护,并显著抑制了来自培养的人肝细胞中入侵和发育的天然疟原虫孢子。这些结果可能表明控制疟原虫孢子感染人类所需的保护性抗体的类型和作用模式,以及诱导保护性长寿命效应记忆 CD8+T 细胞的潜在机制。